With no available therapy for the treatment of fibromyalgia syndrome (FS), pharmaceutical companies have shown great interest in coming up with possible recommendations and therapies for treatment. Central nervous system (CNS) niche disorders have always been a major challenge and FS is no different. Some of the key products in late-stage clinical trials have shown considerable promise and offer high growth opportunities.
New analysis from Frost & Sullivan (http://www.pharma.frost.com/), European Markets for Fibromyalgia Syndrome, finds that the market earned revenues of $73.4 million in 2007 and estimates this to reach $406.3 million in 2013.
"The increasing number of patients being diagnosed with CNS niche disorders, coupled with the lack of drugs to cater to them, has created tremendous scope for new blockbuster products," notes Frost & Sullivan Research Analyst Sriram V. "The absence of effective long-term treatment alternatives for neuropathic pain disorders such as FS has created a large pool of potential patients."
Read the rest of this article here.